Home › NDC Lookup › RxCUI directory › RxCUI 2679812

Selpercatinib 160 MG Oral Tablet [Retevmo] — RxCUI 2679812

RxNorm drug concept · Semantic branded drug
RxCUI 2679812 Semantic branded drug · SBD ● Current RxNorm concept 6 FDA products 7 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2679812
Official nameSelpercatinib 160 MG Oral Tablet [Retevmo]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asRetevmo 160 MG Oral Tablet
FDA products mapped6
Package NDCs mapped7
Reported Medicaid activity (SDUD)159 prescriptions · 4 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Selpercatinib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Selpercatinib only works on tumors driven by a specific change in the RET gene — either a fusion or a mutation. Without that genetic change, the drug has no target to block. The te...
  • Why did my doctor order a genetic test before giving me this medication?
  • This is really important to bring up with your doctor or pharmacist. Common acid-reducing medicines — like omeprazole (Prilosec), famotidine (Pepcid), or even regular antacids — ca...
  • Can I take my heartburn or antacid medicine while I'm on selpercatinib?
📖 Read our full Selpercatinib guide →

🕸️ Concept Web — How Selpercatinib 160 MG Oral Tablet [Retevmo] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Selpercatinib 160 MG Oral Tablet [Retevmo] RxCUI 2679812

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Selpercatinib 2370147
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Retevmo 2370165
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Selpercatinib Oral Tablet 2679804
    • Selpercatinib Oral Product 2370161
    • Selpercatinib Pill 2370162
    • Selpercatinib Oral Tablet [Retevmo] 2679807
    • Retevmo Oral Product 2370168
    • Retevmo Pill 2370169
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Selpercatinib 160 MG Oral Tablet SCD · 2679810
  • Selpercatinib 160 MG SCDC · 2679809
  • Selpercatinib Oral Tablet SCDF · 2679804
  • Selpercatinib Oral Product SCDG · 2370161
  • Selpercatinib Pill SCDG · 2370162

Brand-Name Concepts

  • Selpercatinib 160 MG [Retevmo] SBDC · 2679811
  • Selpercatinib Oral Tablet [Retevmo] SBDF · 2679807
  • Retevmo Oral Product SBDG · 2370168
  • Retevmo Pill SBDG · 2370169
  • Retevmo BN · 2370165

📦 FDA Products & Package NDCs

6 products · 7 package NDCs
7 package NDCs map to RxCUI 2679812 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00002-2980-26 120 CAPSULE in 1 BOTTLE (0002-2980-26) RETEVMO Eli Lilly and Company 2020-05-08
00002-2980-60 60 CAPSULE in 1 BOTTLE (0002-2980-60) RETEVMO Eli Lilly and Company 2020-05-08
00002-3977-60 60 CAPSULE in 1 BOTTLE (0002-3977-60) RETEVMO Eli Lilly and Company 2020-05-08
00002-5340-60 60 TABLET, COATED in 1 BOTTLE (0002-5340-60) RETEVMO Eli Lilly and Company 2024-04-10
00002-5562-60 60 TABLET, COATED in 1 BOTTLE (0002-5562-60) RETEVMO Eli Lilly and Company 2024-04-10
00002-6082-60 60 TABLET, COATED in 1 BOTTLE (0002-6082-60) RETEVMO Eli Lilly and Company 2024-04-10
00002-6120-60 60 TABLET, COATED in 1 BOTTLE (0002-6120-60) RETEVMO Eli Lilly and Company 2024-04-10
Observed labelers: Eli Lilly and Company (7) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.